Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Indian vaccine makers say can quickly adapt to tackle variants

02/22/2021 | 11:47am EST
COVID-19 vaccination in New Delhi

NEW DELHI (Reuters) - Indian pharmaceutical companies Bharat Biotech and Biological E. Ltd said on Monday they could quickly rework their COVID-19 vaccine products to fight new variants once their genetic sequence is known.

In recent months, India has confirmed the presence of the variants first identified in Brazil, Britain and South Africa, which are believed to explain an upsurge in cases in the Indian states of Maharashtra and Kerala.

In all, India has reported more than 11 million coronavirus infections, the highest number in the world after the United States, and about 156,000 deaths.

"As we are seeing a lot of resurgence of cases, we are picking up samples from hotspots and clusters and we are trying to sequence them," Nivedita Gupta, deputy director-general of the state-run Indian Council of Medical Research (ICMR), told the BioAsia conference.

ICMR and Bharat Biotech have collaborated to develop India's first homegrown COVID-19 vaccine, which, along with another licensed from AstraZeneca and Oxford University, is being used in the country's immunisation campaign that has covered more than 10 million people since mid-January.

India is the world's biggest maker of vaccines, and its companies have promised to produce billions of doses of COVID-19 shots.

Bharat Biotech Chairman Krishna Ella said his company would mainly need data from the ICMR or the World Health Organization on the genetic sequence of any variant to quickly make an effective vaccine.

Speaking at a conference organised by the state of Telangana, home to India's vaccine hub Hyderabad, Ella said a product to tackle the South African variant could be made in 15 days and would not require any change to the manufacturing process.

Biological E. Managing Director Mahima Datla said there was no need to be "overly concerned" about the mutations.

"Eventually we don't know which variant of the virus, which mutants will take over, but we think that it's prudent to work on technologies that address the new variants as well," she said.

Biological E., which is developing a vaccine with Houston's Baylor College of Medicine and Dynavax Technologies, recently completed Phase 1/2 clinical trial in India, Datla said.

Its product uses the recombinant-protein technology in which a harmless agent is used to stimulate an immune response in cells.

"Once you know the variant, when it's sequenced, it is fairly quick to deploy into a vaccine," said Datla, whose company will also contract-manufacture Johnson & Johnson's shot.

(Reporting by Krishna N. Das and Neha Arora; editing by Barbara Lewis)

By Krishna N. Das and Neha Arora

© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.24% 7120 Delayed Quote.-2.79%
DYNAVAX TECHNOLOGIES CORPORATION 3.30% 9.38 Delayed Quote.115.73%
All news about ASTRAZENECA PLC
05:14pFDA says single-dose shot from J&J prevents severe COVID
05:14pPFIZER : Israeli Study Finds Pfizer Shot Equally Effective for Young and Old
03:51pASTRAZENECA : Canada heralds first COVAX vaccine in Africa; NDP criticizes Canad..
02:17pAZN INVESTOR ALERT : Bronstein, Gewirtz & Grossman, LLC Notifies AstraZeneca PLC..
12:05pEUROPE : European shares end higher on upbeat German data
12:04pEuropean shares end higher on upbeat German data
11:12aASTRAZENECA : First doses of the AstraZeneca vaccine have been delivered to Ghan..
11:04aASTRAZENECA : First doses of the AstraZeneca vaccine have been delivered to Ghan..
10:56aASTRAZENECA : Johnson & Johnson's one-dose vaccine closes in on U.S. approval
10:32aFDA says J&J 1-dose shot prevents COVID; final decision soon
More news
Financials (USD)
Sales 2021 30 651 M - -
Net income 2021 4 629 M - -
Net Debt 2021 12 157 M - -
P/E ratio 2021 28,2x
Yield 2021 2,83%
Capitalization 132 B 132 B -
EV / Sales 2021 4,71x
EV / Sales 2022 4,06x
Nbr of Employees 76 100
Free-Float 95,8%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 128,36 $
Last Close Price 100,73 $
Spread / Highest target 56,0%
Spread / Average Target 27,4%
Spread / Lowest Target -10,4%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC-2.79%132 114
JOHNSON & JOHNSON1.94%421 745
ROCHE HOLDING AG-2.93%285 334
NOVARTIS AG-6.35%196 152
MERCK & CO., INC.-8.88%188 589
PFIZER INC.-6.93%188 485